Tarsus Pharmaceuticals, Inc. reported $606M of revenue over the trailing twelve months, +105% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $606M (to Q2 2026). Net income: −$46M, trailing twelve months to Q2 2026. Free cash flow: $56M, trailing twelve months to Q2 2026. Operating margin: −8.2%, trailing twelve months to Q2 2026.

TARSTarsus Pharmaceuticals, Inc.

Healthcare

$73.14+33% 1Y

$73.14

$55.2652 weeks$90.81

TARS as reported

Tarsus Pharmaceuticals, Inc. reported $606M of revenue over the trailing twelve months, +105% on the year before. 9 reported series are charted on this page, each one as filed.

$606M

Revenue, trailing twelve months · to Q2 2026 · +105% against the twelve months before

Net income: −$46M
Net income · −49% year on year · trailing twelve months to Q2 2026
Free cash flow: $56M
Free cash flow · −168% year on year · trailing twelve months to Q2 2026
Operating margin: −8.2%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for TARS, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$606M	+105%	Q2 2026
Net income	−$46M	−49%	Q2 2026
EPS	−$1.08	−53%	Q2 2026
Operating margin	−8.2%	n/a	Q2 2026
Net margin	−7.8%	n/a	Q2 2026
ROE	−18%	n/a	Q2 2026
ROA	−11%	n/a	Q2 2026
ROIC	688%	n/a	Q2 2026
Free cash flow	$56M	−168%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.